Open-Label Safety Extension Study of Avonex

Summary

To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.

Timeline

Start

1999-09

Primary completion

2003-06

Completion

2003-07

Drugs

Indications